Water soluble farnesol analogs and their use

US10532124B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10532124-B2
Application numberUS-201214655359-A
CountryUS
Kind codeB2
Filing dateDec 27, 2012
Priority dateDec 27, 2012
Publication dateJan 14, 2020
Grant dateJan 14, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Farnesol analogs, along with their related products (e.g., treatment compositions, wipes, absorbent articles, etc.) and their methods of formation, are provided. The farnesol analog includes a hydrophilic end group (e.g., a hydroxyl end group or a carboxylic acid end group) attached to farnesol via a covalent linkage (e.g., an ester group or an ether group).

First claim

Opening claim text (preview).

What is claimed is: 1. A farnesol analog comprising a hydrophilic end group attached to farnesol via a covalent linkage, wherein the hydrophilic end group defines a hydroxyl end group, and wherein the covalent linkage comprises an ester group or an ether group, wherein the farnesol analog comprises one of the structures: where n is an integer from 1 to 8; m is an integer from 1 to 8; and p is an integer from 1 to 100. 2. The farnesol analog as in claim 1 , wherein the covalent linkage comprises an ester group. 3. The farnesol analog as in claim 1 , wherein n is 2, 3, or 4. 4. The farnesol analog as in claim 3 , wherein the hydrophilic end group comprises an ester group. 5. The farnesol analog as in claim 1 , wherein n is 2, 3, or 4; and wherein m is 2, 3, or 4. 6. The farnesol analog as in claim 1 , wherein the covalent linkage comprises an ether group, and wherein the hydrophilic end group defines a hydroxyl end group. 7. The farnesol analog as in claim 1 , wherein the farnesol analog has a solubility in water that is 10 grams per 100 grams of water or greater. 8. A web comprising a plurality of fibers, wherein the web is coated with a treatment composition, the treatment composition comprising a farnesol analog according to claim 1 . 9. An absorbent article comprising: a liquid impermeable outer cover; a liquid permeable bodyside liner, wherein the bodyside liner comprises the web according to claim 8 ; and an absorbent body disposed between the outer cover and bodyside liner. 10. A method of forming a farnesol analog that is soluble in water from a farnesol molecule having a hydroxyl group, the method comprising: covalently attaching a hydrophilic end group to the farnesol molecule via reaction with its hydroxyl group to form a covalent linkage, wherein the hydrophilic end group defines a hydroxyl end group, and wherein the covalent linkage comprises an ester group or an ether group, wherein the farnesol analog comprises one of the structures: where n is an integer from 1 to about 8; m is an integer from 1 to 8; and p is an integer from 1 to 100. 11. The method as in claim 10 , wherein the covalent linkage comprises an ester group formed via an esterification reaction between the hydroxyl group of the farnesol molecule and a carboxylic acid functional molecule. 12. The method as in claim 11 , further comprising: reacting the carboxylic acid end group with a glycol via a second esterification reaction to form a farnesol analog having a hydroxyl group covalently attached via two ester linkages. 13. The method as in claim 12 , wherein the glycol is selected from the group consisting of ethylene glycol, propylene glycol, and butane-1,4-diol. 14. The method as in claim 10 , wherein the covalent linkage comprises an ether group formed by reacting farnesol with an alcohol via a dehydration reaction to form the ether group. 15. The method as in claim 14 , wherein the alcohol is a glycol selected from the group consisting of ethylene glycol, propylene glycol, and butane-1,4-diol. 16. The method as in claim 14 , wherein the hydrophilic end group comprises a sugar. 17. A wipe comprising the web according to claim 8 .

Assignees

Inventors

Classifications

  • Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom · CPC title

  • Acyclic alcohols with carbon-to-carbon double bonds · CPC title

  • A61L15/44Primary

    Medicaments · CPC title

  • A61L15/20Primary

    containing organic materials · CPC title

  • {Compostable,} hydrosoluble or hydrodegradable materials · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10532124B2 cover?
Farnesol analogs, along with their related products (e.g., treatment compositions, wipes, absorbent articles, etc.) and their methods of formation, are provided. The farnesol analog includes a hydrophilic end group (e.g., a hydroxyl end group or a carboxylic acid end group) attached to farnesol via a covalent linkage (e.g., an ester group or an ether group).
Who is the assignee on this patent?
Kimberly Clark Co
What technology area does this patent fall under?
Primary CPC classification A61L15/44. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).